Ad is loading...
MENU

EXAS Stock Exact Sciences (EXAS, $70.96) price may drop as it broke higher Bollinger Band on Oct 11, 2024

A.I.dvisor
at Tickeron.com
Loading...
EXAS - Exact Sciences Corp
Bollinger signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Bollinger signal
Price: $70.96
Daily change: +$1.62 (+2.34%)
Daily volume: 1.2M
Industry: Medical Specialties
This price move could be a signal that EXAS may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 36 similar cases where EXAS's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:

EXAS in downward trend: price dove below 50-day moving average on November 06, 2024

EXAS moved below its 50-day moving average on November 06, 2024 date and that indicates a change from an upward trend to a downward trend. In of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for EXAS crossed bearishly below the 50-day moving average on November 07, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXAS's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 22, 2024. You may want to consider a long position or call options on EXAS as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .

EXAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 216 cases where EXAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.065) is normal, around the industry mean (22.933). P/E Ratio (0.000) is within average values for comparable stocks, (83.945). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.074) is also within normal values, averaging (43.174).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EXAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

View a ticker or compare two or three
EXAS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary technologies for the detection of cancer

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
5505 Endeavor Lane
Phone
+1 608 284-5700
Employees
6600
Web
https://www.exactsciences.com